TW202340249A - 生物活性降低之抗體變體 - Google Patents

生物活性降低之抗體變體 Download PDF

Info

Publication number
TW202340249A
TW202340249A TW111149176A TW111149176A TW202340249A TW 202340249 A TW202340249 A TW 202340249A TW 111149176 A TW111149176 A TW 111149176A TW 111149176 A TW111149176 A TW 111149176A TW 202340249 A TW202340249 A TW 202340249A
Authority
TW
Taiwan
Prior art keywords
antibody
nemolizumab
pharmaceutical composition
variant
monoclonal antibody
Prior art date
Application number
TW111149176A
Other languages
English (en)
Chinese (zh)
Inventor
細口健作
原愛
増田宗太
髙城美智
南部周介
佐藤久美
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202340249A publication Critical patent/TW202340249A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111149176A 2021-12-22 2022-12-21 生物活性降低之抗體變體 TW202340249A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-207714 2021-12-22
JP2021207714 2021-12-22

Publications (1)

Publication Number Publication Date
TW202340249A true TW202340249A (zh) 2023-10-16

Family

ID=86902603

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111149176A TW202340249A (zh) 2021-12-22 2022-12-21 生物活性降低之抗體變體

Country Status (7)

Country Link
US (1) US20250163163A1 (https=)
EP (1) EP4455163A4 (https=)
JP (3) JP7721630B2 (https=)
KR (2) KR102902883B1 (https=)
CN (1) CN118613503A (https=)
TW (1) TW202340249A (https=)
WO (1) WO2023120561A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101225299B1 (ko) * 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN119161488A (zh) * 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
JP7840636B2 (ja) * 2018-04-02 2026-04-06 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Also Published As

Publication number Publication date
KR102902883B1 (ko) 2025-12-22
JPWO2023120561A1 (https=) 2023-06-29
JP7721630B2 (ja) 2025-08-12
JP7812826B2 (ja) 2026-02-10
CN118613503A (zh) 2024-09-06
JP2026063423A (ja) 2026-04-10
WO2023120561A1 (ja) 2023-06-29
JP2023159309A (ja) 2023-10-31
EP4455163A1 (en) 2024-10-30
KR20240117039A (ko) 2024-07-31
KR20260007630A (ko) 2026-01-14
EP4455163A4 (en) 2025-12-24
US20250163163A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
US20230060847A1 (en) Anti-bcma heavy chain-only antibodies
JP7303126B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP5513888B2 (ja) グルカゴン受容体抗体に関する組成物および方法
AU2016223095B2 (en) Antibodies to tau and uses thereof
TW202005982A (zh) 拮抗cd73之抗體
JP2021503280A (ja) 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
CN110898220B (zh) 抗IL17a抗体的水性药物组合物及其用途
RS63513B1 (sr) Anti-transtiretin antitela
JP7595567B2 (ja) 抗ｆｇｆｒ２抗体製剤
TW202128131A (zh) 重組抗程式性細胞死亡受體1和抗分化抗原簇137雙特異性抗體製劑及其用途
EP3873934A2 (en) Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
CN105085679B (zh) 全人源抗rankl抗体
JP2026063423A (ja) 生物活性が低下した抗体バリアント
JP7602485B2 (ja) 抗ｃｄ３８抗体および製剤
CN119604764A (zh) 免疫调节剂的筛选和制备方法
JP2022539088A (ja) 抗ｌａｇ‐３抗体を含む製剤、その調製方法及び使用
HK40108969A (zh) 生物学活性降低的抗体变体
KR20260058849A (ko) 항-tslp 항체 작제물 및 이의 용도
WO2025221933A1 (en) Antibodies and polypeptides comprising variant fc regions
BR122024025945A2 (pt) Anticorpos com apenas cadeia pesada anti-bcma, uso e método de produção dos mesmos, células, composição farmacêutica, polinucleotídeo e vetor
BR122024024664A2 (pt) Anticorpos apenas de cadeia pesada anti-bcma, seu método de produção e uso, composição farmacêutica, polinucleotídeo, vetor e célula